Notably, treatment usage trends from a Bladder Cancer Advocacy Network (BCAN) survey presented at GU ASCO 2025 revealed that only 1–5% of patients reported having seen a radiation oncologist and only ...

Perioperative management for muscle invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy and risk-adapted adjuvant immunotherapy. More ...

Researchers from the University of California, Irvine, led by Nazmul Hasan, reviewed recent clinical and scientific advances in combining radiation therapy with immunotherapy for bladder cancer. The ...

Immune checkpoint blockades (ICBs) have revolutionized cancer therapy through unleashing anti-tumor adaptive immunity. Despite that, they are usually effective only in a small subset of patients and ...

Combination therapy with imlunestrant and the CDK4/6 ... growth factor receptor 2 (HER2)–negative advanced breast cancer who had experienced disease progression following CDK4/6 inhibitor ...

Sam Chang presented an update on the QUILT-3.032 trial, showing that the combination of N-803 (ANKTIVA) plus BCG therapy achieved a 71% complete ... offering a more efficient and sensitive approach ...

Risk Stratification Systems: The panel discussed various risk classification systems for non–muscle-invasive bladder cancer (NMIBC), comparing AUA ... for when patients should discontinue BCG therapy.

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook candle light in church with blurry golden bokeh for religious ritual or spiritual zen meditation, ...

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD. Data presented at the 2025 American Urological Association (AUA) Annual Meeting ...

The approval was based on results from the phase 2 LITESPARK-015 trial. The US Food and Drug Administration (FDA) has approved Welireg (belzutifan) for the treatment of patients aged 12 years and ...

AbbVie and ADARx signed a $335 million upfront siRNA therapy deal, with potential for billions in milestones and royalties. Get stock picks, daily rankings, and pro-level trading tools in one ...